DayTwo is committed to creating individualized solutions for the epidemic of chronic conditions, starting with diabetes, prediabetes, and clinical obesity. It is the only company that can predict blood sugar response to any foods before people even take a bite. DayTwo’s precision health solution uses gut microbiome profiling, artificial intelligence, and virtual care to deliver food recommendations matched to individual biology. Backed by 10 years of science and the world’s largest microbiome discovery platform, the DayTwo program sets a new national benchmark in proactive, personalized care. Join CEO David Henderson to learn more about how DayTwo’s clinical discoveries and IP will revolutionize the chronic disease space for years to come.